



Platinum-Based Therapeutics for Cancers

Guest Editors:

Dr. Monica Montopoli

Department of Pharmaceutical
and Pharmacological Sciences,
University of Padova, Padova,
Italy

Dr. Veronica Cocetta

Department of Pharmaceutical
and Pharmacological Sciences,
University of Padova, Padova,
Italy

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editors

Dear Colleagues,

Despite the recent clinical introduction of immunotherapy, platinum-based agents, such as cisplatin, carboplatin, and oxaliplatin, still remain the most used drugs in chemotherapy for the treatment of solid tumors. In addition to the severe toxicity of platinum-based drugs, such as nephrotoxicity, ototoxicity, and peripheral neurotoxicity, the onset of drug resistance represents one of the main issues related to their clinical use. In light of these considerations, there is still the need to keep investigating this field.

Research areas may include (but are not limited to) the following:

- Deepening the current knowledge about platinum-based therapeutics' implications in cancer
- Investigating the molecular mechanisms involved in platinum-based agents cancer resistance and the possible emerging strategies to overcome it (thus, we encourage new research articles related to monotherapy or combined approaches, as well as the application of drug delivery systems)
- Untangling the role of the tumor microenvironment in the onset of platinum agents' resistance
- Investigating if gender difference is involved in patients' response to treatment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)